scholarly journals Effect of Citrulline and Leucine Intake with Exercises on Body Composition, Physical Activity, and Amino Acid Concentration in Older Women: A Randomized Double-Blind Placebo-Controlled Study

Foods ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3117
Author(s):  
Mijin Kim ◽  
Hiroko Isoda ◽  
Tomohiro Okura
Keyword(s):  
Physical Activity ◽  
Body Composition ◽  
Body Weight ◽  
Amino Acid ◽  
Older Women ◽  
Body Mass ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Amino Acid Concentrations

The combined intake of citrulline (CIT) and leucine (LEU) can stimulate protein synthesis. Therefore, this study aimed to investigate the effect of combined intake of CIT and LEU accompanied by exercise for 20 weeks on body composition, physical activity (PA), and amino acid concentrations in older Japanese women with low body mass index (BMI) (16 to 21 kg/m2) using a randomized, double-blind, placebo-controlled design. The supplement was administered twice a day for 20 weeks (Ex (exercise) + CIT·LEU group, n = 10: mainly 0.8 g CIT and 1.6 g LEU; Ex + Placebo group, n = 13: mainly 3.5 g carbohydrate). Additionally, both groups exercised (weight-bearing exercise, square stepping exercise) once a week for 75 min. Body composition, PA, and amino acid concentrations in the plasma were measured. Body weight, BMI, body mass, household PA, total PA, and phenylalanine significantly increased in the Ex + CIT·LEU group (p < 0.05) post intervention. This study suggests that the combined intake of CIT and LEU accompanied by exercise can improve body weight, BMI, body mass, and PA in older women with low BMI, which may prevent sarcopenia and frailty.

scholarly journals Effect of L-citrulline, L-leucine, and multicomponent exercises on body compositions, physical activity, and amino acid concentrations in older Japanese women with low body mass index: A randomized double-blind placebo-controlled study

2021 ◽  
Author(s):  
Mijin Kim ◽  
Hiroko Isoda ◽  
Tomohiro Okura
Keyword(s):  
Physical Activity ◽  
Body Mass Index ◽  
Body Composition ◽  
Body Weight ◽  
Amino Acid ◽  
Bone Mass ◽  
Older Women ◽  
Body Mass ◽  
Low Body Mass Index ◽  
Amino Acid Concentrations

Abstract Background: The intake of citrulline (CIT) and leucine (LEU) can stimulate protein synthesis. However, the efficacy of the combined intervention of CIT and LEU intake with exercise on body composition and physical activity (PA) remains unclear. This study aimed to investigate the combined effect of CIT and LEU intake and weight-bearing exercises (WBE) and square stepping exercise (SSE) for 20 weeks on body composition, PA, and amino acid concentration in older women with low body mass index (BMI) (16 to 21 kg/m 2 ). Methods: A total of 23 participants practiced WBE and SSE once a week for 75 minutes and were administered supplement (Ex + CIT·LEU group: CIT 0.8 g and LEU 1.6 g; Ex + Placebo group: 3.5 g carbohydrate) twice a day for 20 weeks. Body composition was measured using dual-energy X-ray absorptiometry. PA, including leisure-time, household, and occupational PA, was assessed using the Physical Activity Scale for the Elderly. Amino acid concentrations in the blood were analyzed by high-performance liquid chromatography.Results: Significant interactions were observed in the body weight, BMI, lean mass, body mass, household and total PA, tyrosine, and phenylalanine. The within-group analysis showed that tyrosine of post-intervention measurement (Post) significantly in both groups ( p < 0.05). Body weight, BMI, lean mass, body mass, household PA, total PA, and phenylalanine of Post increased significantly in the Ex + CIT·LEU group ( p < 0.05). Additionally, significant positive correlations were observed between the intake rate of supplements and bone mass ( r = 0.80) and between the practice rate of WBE at home and bone mineral density ( r = 0.66) in the Ex + CIT·LEU group. Conclusion: Our findings suggest that the intake of CIT and LEU, with the practice of WBE and SSE, could improve body weight, muscle mass, bone mass, and PA in older women with low BMI, which may prevent sarcopenia and frailty.Trial registration: UMIN000022385. Registered 20 May 2016, https://upload.umin.ac.jp/cgi-open-39 bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000025797&type=summary&language=J

scholarly journals A randomized, double-blind, placebo-controlled study of liraglutide 3 mg [LIRA 3mg] on weight, body composition, hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome (PCOS)

2021 ◽  
Author(s):  
Karen Elkind-Hirsch ◽  
Neil Chappell ◽  
Donna Shaler ◽  
John Storment ◽  
Drake Bellanger
Keyword(s):  
Body Composition ◽  
Body Weight ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Change In Mean

Abstract BackgroundThe efficacy of lifestyle modifications for established obesity is limited in women with polycystic ovary syndrome (PCOS) and more aggressive interventions are needed. We assessed the efficacy and safety of the GLP-1 analogue liraglutide 3mg (LIRA 3mg) versus placebo (PL) for reduction of body weight and hyperandrogenism in women with obesity and PCOSMethodsThis randomized, double-blind, placebo-controlled study enrolled women from a single-outpatient center diagnosed with PCOS (NIH criteria) with a body-mass index of at least 30 kg/m.2 Participants were randomly allocated (2:1) to treatment with a subcutaneous injection LIRA 3mg or visually matching placebo, once daily for 32 weeks, plus lifestyle intervention. Study visits at baseline, and 32 weeks included weight, blood pressure (BP), waist (WC) measures and body composition evaluated by dual-energy X-ray absorptiometry (DXA). Oral glucose tolerance tests (OGTT) were done to assess glycemia, mean blood glucose (MBG), and compute insulin sensitivity (SI) and secretion (IS) measures. Sex steroids, free androgen index (FAI), complete metabolic profile and lipid profiles were measured in the fasting sample. Co-primary endpoints were change in body weight (BW) and FAI. Safety was assessed in all patients who received at least one dose of study drug. This study was registered with ClinicalTrials.gov NCT03480022FindingsFrom October 2018 to June 2020, 88 patients were screened, of whom 82 were randomly assigned to LIRA 3mg (n = 55) or PL (n = 27). Change in mean BW from baseline to week 32 was − 5.7% (SE 0·.75) with LIRA 3mg vs. -1.4% (1.09) with PL (P < 0.002). At week 32, more patients on LIRA 3 mg than on placebo achieved weight reductions of at least 5% (25[57%] of 44 vs. 5 [22%] of 23; (p < 0·007). LIRA 3mg resulted in significant reduction of FAI, improvements in SI and IS as well as OGTT MBG, and improved body fat by DXA. Gastrointestinal adverse events, which were mostly mild to moderate, were reported in 32 (58.2%) of 55 patients with LIRA 3mg, and 5 (18.5%) of 27 with PL.InterpretationIn obese women with PCOS, LIRA 3mg once daily achieved a superior and clinically meaningful decrease in BW and androgenicity and improved cardiometabolic parameters compared with placebo.

scholarly journals The effects of steamed ginger ethanolic extract on weight and body fat loss: a randomized, double-blind, placebo-controlled clinical trial

2019 ◽  
Vol 29 (2) ◽  
pp. 265-273 ◽  
Author(s):  
Soo-Hyun Park ◽  
Su-Jin Jung ◽  
Eun-Kyung Choi ◽  
Ki-Chan Ha ◽  
Hyang-Im Baek ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Body Mass Index ◽  
Body Weight ◽  
Body Mass ◽  
Body Fat ◽  
Ethanolic Extract ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Fat Loss

Abstract Steamed ginger ethanolic extract (SGE) is a product with a high 6-shogaol contents and is thought to be more potent than other ginger products. We conducted a 12-week, randomized, double-blind, placebo-controlled clinical trial to determine the effects of SGE on weight and body fat loss. Eighty healthy obese participants were recruited and randomly divided into the SGE and placebo groups. The outcome measures comprised indicators of efficacy (body weight, body mass index, body composition, and blood markers) and safety. Following the supplementation period, mean body weight, body mass index, and body fat level were significantly lower in the SGE group than in the placebo group. No clinically significant changes were observed for any safety parameter. These results suggest that SGE is a potent anti-obesity agent that does not cause significant side effects. Therefore, SGE supplementation combined with lifestyle modification could be effective in the management of body weight and fat mass.

scholarly journals Seaweed Fucoxanthin Supplementation Improves Obesity Parameters in Mild Obese Japanese Subjects

2017 ◽  
Vol 7 (4) ◽  
pp. 246 ◽  
Author(s):  
Shoketsu Hitoe ◽  
Hiroshi Shimoda
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Placebo Group ◽  
Body Mass ◽  
Subcutaneous Fat ◽  
Abdominal Fat ◽  
Thigh Circumference ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Obese Subjects

Background: Fucoxanthin is a seaweed xanthophyll that has demonstrated an anti-obesity effect in rodents. However, clinical investigations of its influence on mildly obese subjects has not been performed. We conducted a clinical trial of fucoxanthin supplementation in Japanese obese subjects. Methods: We examined the effect of fucoxanthin (1 or 3 mg daily) in a double-blind placebo-controlled study. Capsules containing fucoxanthin or placebo capsules were administered for 4 weeks to male and female Japanese adults with a body mass index (BMI) of more than 25 kg/m2. Before and after treatment, the body weight, body composition, abdominal fat area, and the circumferences of the neck, arm, and thigh were evaluated.Results: There was significant reduction of the relative (ratio versus before treatment) body weight, BMI, and visceral fat area in the 3 mg/day fucoxanthin group compared to the placebo group. Relative values of total fat mass, subcutaneous fat area, waist circumference, and right thigh circumference were also significantly lower in the 1 mg/day fucoxanthin group than the placebo group. A significant decrease of the absolute right thigh circumference was noted in the 1 mg/day fucoxanthin group compared to the placebo group. In the subjects ingesting fucoxanthin, there were no abnormalities of the blood pressure, pulse rate, blood parameters, and urinalysis parameters, which thereby suggests adverse effects. Conclusions: Fucoxanthin reduced body weight, BMI, and abdominal fat by acting on both visceral and subcutaneous fat. Consequently, Fucoxanthin may be able to improve a moderate overweight state in both men and women. Keywords: Randomized, double-blind, placebo-controlled crossover trial; fucoxanthin; body mass index; body weight; subcutaneous fat; adipose tissue

Sign in / Sign up

Export Citation Format

Share Document